Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.

Saved in:
Bibliographic Details
Title: Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
Authors: Jackovich A; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Gitlitz BJ; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Tiu-Lim JWW; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Duddalwar V; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., King KG; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., El-Khoueiry AB; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Thomas JS; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Tsao-Wei D; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Quinn DI; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA., Gill PS; Rutgers New Jersey Medical School, Newark, NJ 07103, USA., Nieva JJ; Rutgers New Jersey Medical School, Newark, NJ 07103, USA.; Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.
Source: Oncotarget [Oncotarget] 2024 Jul 10; Vol. 15, pp. 444-458. Date of Electronic Publication: 2024 Jul 10.
Publication Type: Journal Article; Clinical Trial, Phase II; Research Support, N.I.H., Extramural
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Electronic Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1949-2553
DOI:10.18632/oncotarget.28605